APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Platinum-based Anticancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Platinum-based Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174026660320 December 2025190 pages

Choose your research edition.

Industry ResearchPlatinum-based Anticancer Drugs Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Platinum-based Anticancer Drugs Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Platinum-based Anticancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platinum-based Anticancer Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Platinum-based Anticancer Drugs Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Platinum-based Anticancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Platinum-based Anticancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Platinum-based Anticancer Drugs include Teva, Sun Pharmaceutical, Qilu Pharmaceutical, Nanjing Pharmaceutical Factory, Mylan, Luoxin, Jiangsu Aosaikang Pharmaceutical, Jiangsu Hengrui Medicine and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Platinum-based Anticancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Platinum-based Anticancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Platinum-based Anticancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Platinum-based Anticancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Platinum-based Anticancer Drugs Segment by Company

Teva

Sun Pharmaceutical

Qilu Pharmaceutical

Nanjing Pharmaceutical Factory

Mylan

Luoxin

Jiangsu Aosaikang Pharmaceutical

Jiangsu Hengrui Medicine

Fresenius Kabi

Yakult honsha

Taj Pharmaceuticals

Sanofi-Aventis

Lingnan Pharmacy

Hospira(Pfizer)

Hisun Pharmaceutical

Hansoh Pharma

Dr Reddy's laboratories

Platinum-based Anticancer Drugs Segment by Type

Oxaliplatin

Carboplatin

Nedaplatin

Cisplatin

Others

Platinum-based Anticancer Drugs Segment by Application

Esophageal Cancer

Breast Cancer

Osteosarcoma

Testicular Cancer

NSCLC

Other

Platinum-based Anticancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Anticancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Anticancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Anticancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Platinum-based Anticancer Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Platinum-based Anticancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Platinum-based Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Platinum-based Anticancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Platinum-based Anticancer Drugs Industry Trends Table 2. Platinum-based Anticancer Drugs Industry Drivers Table 3. Platinum-based Anticancer Drugs Industry Opportunities and Challenges Table 4. Platinum-based Anticancer Drugs Industry Restraints Table 5. Global Platinum-based Anticancer Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Platinum-based Anticancer Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Platinum-based Anticancer Drugs Sales by Manufacturers (Tons) & (2021-2026) Table 8. Global Platinum-based Anticancer Drugs Sales Market Share by Manufacturers Table 9. Global Platinum-based Anticancer Drugs Average Sales Price (US$/Ton) of Manufacturers (2021-2026) Table 10. Global Platinum-based Anticancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Platinum-based Anticancer Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Platinum-based Anticancer Drugs Manufacturers, Product Type & Application Table 13. Global Platinum-based Anticancer Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Platinum-based Anticancer Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Oxaliplatin Table 17. Major Manufacturers of Carboplatin Table 18. Major Manufacturers of Nedaplatin Table 19. Major Manufacturers of Cisplatin Table 20. Major Manufacturers of Others Table 21. Global Platinum-based Anticancer Drugs Sales by Type 2021 VS 2025 VS 2032 (Tons) Table 22. Global Platinum-based Anticancer Drugs Sales by Type (2021-2026) & (Tons) Table 23. Global Platinum-based Anticancer Drugs Sales by Type (2027-2032) & (Tons) Table 24. Global Platinum-based Anticancer Drugs Sales Market Share by Type (2021-2026) Table 25. Global Platinum-based Anticancer Drugs Sales Market Share by Type (2027-2032) Table 26. Global Platinum-based Anticancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (Tons) Table 27. Global Platinum-based Anticancer Drugs Revenue by Type (2021-2026) & (Tons) Table 28. Global Platinum-based Anticancer Drugs Revenue by Type (2027-2032) & (Tons) Table 29. Global Platinum-based Anticancer Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Platinum-based Anticancer Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Esophageal Cancer Table 32. Major Manufacturers of Breast Cancer Table 33. Major Manufacturers of Osteosarcoma Table 34. Major Manufacturers of Testicular Cancer Table 35. Major Manufacturers of NSCLC Table 36. Major Manufacturers of Other Table 37. Global Platinum-based Anticancer Drugs Sales by Application 2021 VS 2025 VS 2032 (Tons) Table 38. Global Platinum-based Anticancer Drugs Sales by Application (2021-2026) & (Tons) Table 39. Global Platinum-based Anticancer Drugs Sales by Application (2027-2032) & (Tons) Table 40. Global Platinum-based Anticancer Drugs Sales Market Share by Application (2021-2026) Table 41. Global Platinum-based Anticancer Drugs Sales Market Share by Application (2027-2032) Table 42. Global Platinum-based Anticancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (Tons) Table 43. Global Platinum-based Anticancer Drugs Revenue by Application (2021-2026) & (Tons) Table 44. Global Platinum-based Anticancer Drugs Revenue by Application (2027-2032) & (Tons) Table 45. Global Platinum-based Anticancer Drugs Revenue Market Share by Application (2021-2026) Table 46. Global Platinum-based Anticancer Drugs Revenue Market Share by Application (2027-2032) Table 47. Global Platinum-based Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 48. Global Platinum-based Anticancer Drugs Sales by Region (2021-2026) & (Tons) Table 49. Global Platinum-based Anticancer Drugs Sales Market Share by Region (2021-2026) Table 50. Global Platinum-based Anticancer Drugs Sales Forecasted by Region (2027-2032) & (Tons) Table 51. Global Platinum-based Anticancer Drugs Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 53. North America Platinum-based Anticancer Drugs Sales by Country (2021-2026) & (Tons) Table 54. North America Platinum-based Anticancer Drugs Sales by Country (2027-2032) & (Tons) Table 55. Europe Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 56. Europe Platinum-based Anticancer Drugs Sales by Country (2021-2026) & (Tons) Table 57. Europe Platinum-based Anticancer Drugs Sales by Country (2027-2032) & (Tons) Table 58. Asia Pacific Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 59. Asia Pacific Platinum-based Anticancer Drugs Sales by Country (2021-2026) & (Tons) Table 60. Asia Pacific Platinum-based Anticancer Drugs Sales by Country (2027-2032) & (Tons) Table 61. South America, Middle East and Africa Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Tons) Table 62. South America, Middle East and Africa Platinum-based Anticancer Drugs Sales by Country (2021-2026) & (Tons) Table 63. South America, Middle East and Africa Platinum-based Anticancer Drugs Sales by Country (2027-2032) & (Tons) Table 64. Global Platinum-based Anticancer Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Platinum-based Anticancer Drugs Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Platinum-based Anticancer Drugs Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Platinum-based Anticancer Drugs Revenue Market Share by Region (2021-2026) Table 68. Global Platinum-based Anticancer Drugs Revenue Market Share by Region (2027-2032) Table 69. Teva Company Information Table 70. Teva Business Overview Table 71. Teva Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Teva Platinum-based Anticancer Drugs Product Portfolio Table 73. Teva Recent Development Table 74. Sun Pharmaceutical Company Information Table 75. Sun Pharmaceutical Business Overview Table 76. Sun Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 78. Sun Pharmaceutical Recent Development Table 79. Qilu Pharmaceutical Company Information Table 80. Qilu Pharmaceutical Business Overview Table 81. Qilu Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Qilu Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 83. Qilu Pharmaceutical Recent Development Table 84. Nanjing Pharmaceutical Factory Company Information Table 85. Nanjing Pharmaceutical Factory Business Overview Table 86. Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Product Portfolio Table 88. Nanjing Pharmaceutical Factory Recent Development Table 89. Mylan Company Information Table 90. Mylan Business Overview Table 91. Mylan Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Mylan Platinum-based Anticancer Drugs Product Portfolio Table 93. Mylan Recent Development Table 94. Luoxin Company Information Table 95. Luoxin Business Overview Table 96. Luoxin Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Luoxin Platinum-based Anticancer Drugs Product Portfolio Table 98. Luoxin Recent Development Table 99. Jiangsu Aosaikang Pharmaceutical Company Information Table 100. Jiangsu Aosaikang Pharmaceutical Business Overview Table 101. Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 103. Jiangsu Aosaikang Pharmaceutical Recent Development Table 104. Jiangsu Hengrui Medicine Company Information Table 105. Jiangsu Hengrui Medicine Business Overview Table 106. Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Product Portfolio Table 108. Jiangsu Hengrui Medicine Recent Development Table 109. Fresenius Kabi Company Information Table 110. Fresenius Kabi Business Overview Table 111. Fresenius Kabi Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Fresenius Kabi Platinum-based Anticancer Drugs Product Portfolio Table 113. Fresenius Kabi Recent Development Table 114. Yakult honsha Company Information Table 115. Yakult honsha Business Overview Table 116. Yakult honsha Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Yakult honsha Platinum-based Anticancer Drugs Product Portfolio Table 118. Yakult honsha Recent Development Table 119. Taj Pharmaceuticals Company Information Table 120. Taj Pharmaceuticals Business Overview Table 121. Taj Pharmaceuticals Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Taj Pharmaceuticals Platinum-based Anticancer Drugs Product Portfolio Table 123. Taj Pharmaceuticals Recent Development Table 124. Sanofi-Aventis Company Information Table 125. Sanofi-Aventis Business Overview Table 126. Sanofi-Aventis Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Sanofi-Aventis Platinum-based Anticancer Drugs Product Portfolio Table 128. Sanofi-Aventis Recent Development Table 129. Lingnan Pharmacy Company Information Table 130. Lingnan Pharmacy Business Overview Table 131. Lingnan Pharmacy Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Lingnan Pharmacy Platinum-based Anticancer Drugs Product Portfolio Table 133. Lingnan Pharmacy Recent Development Table 134. Hospira(Pfizer) Company Information Table 135. Hospira(Pfizer) Business Overview Table 136. Hospira(Pfizer) Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Hospira(Pfizer) Platinum-based Anticancer Drugs Product Portfolio Table 138. Hospira(Pfizer) Recent Development Table 139. Hisun Pharmaceutical Company Information Table 140. Hisun Pharmaceutical Business Overview Table 141. Hisun Pharmaceutical Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Hisun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio Table 143. Hisun Pharmaceutical Recent Development Table 144. Hansoh Pharma Company Information Table 145. Hansoh Pharma Business Overview Table 146. Hansoh Pharma Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Hansoh Pharma Platinum-based Anticancer Drugs Product Portfolio Table 148. Hansoh Pharma Recent Development Table 149. Dr Reddy's laboratories Company Information Table 150. Dr Reddy's laboratories Business Overview Table 151. Dr Reddy's laboratories Platinum-based Anticancer Drugs Sales (Tons), Price (US$/Ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Dr Reddy's laboratories Platinum-based Anticancer Drugs Product Portfolio Table 153. Dr Reddy's laboratories Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Platinum-based Anticancer Drugs Distributors List Table 157. Platinum-based Anticancer Drugs Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Platinum-based Anticancer Drugs Product Image Figure 2. Global Platinum-based Anticancer Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platinum-based Anticancer Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Platinum-based Anticancer Drugs Sales (2021-2032) & (Tons) Figure 5. Global Platinum-based Anticancer Drugs Average Price (US$/Ton) & (2021-2032) Figure 6. Global Top 5 and 10 Platinum-based Anticancer Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Oxaliplatin Image Figure 9. Carboplatin Image Figure 10. Nedaplatin Image Figure 11. Cisplatin Image Figure 12. Others Image Figure 13. Global Platinum-based Anticancer Drugs Sales by Type (2021 VS 2025 VS 2032) & (Tons) Figure 14. Global Platinum-based Anticancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Platinum-based Anticancer Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Platinum-based Anticancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (Tons) Figure 17. Global Platinum-based Anticancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Platinum-based Anticancer Drugs Revenue Market Share by Type (2021-2032) Figure 19. Esophageal Cancer Image Figure 20. Breast Cancer Image Figure 21. Osteosarcoma Image Figure 22. Testicular Cancer Image Figure 23. NSCLC Image Figure 24. Other Image Figure 25. Global Platinum-based Anticancer Drugs Sales by Application (2021 VS 2025 VS 2032) & (Tons) Figure 26. Global Platinum-based Anticancer Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Platinum-based Anticancer Drugs Sales Market Share by Application (2021-2032) Figure 28. Global Platinum-based Anticancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (Tons) Figure 29. Global Platinum-based Anticancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Platinum-based Anticancer Drugs Revenue Market Share by Application (2021-2032) Figure 31. North America Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 32. North America Platinum-based Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 33. U.S. Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 34. Canada Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 35. Mexico Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 36. Europe Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 37. Europe Platinum-based Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 38. Germany Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 39. France Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 40. U.K. Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 41. Italy Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 42. Netherlands Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 43. Asia Pacific Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 44. Asia Pacific Platinum-based Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 45. China Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 46. Japan Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 47. South Korea Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 48. Southeast Asia Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 49. India Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 50. Australia Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 51. South America, Middle East and Africa Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 52. South America, Middle East and Africa Platinum-based Anticancer Drugs Sales Market Share by Country (2021-2032) Figure 53. Brazil Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 54. South Africa Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 55. Saudi Arabia Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 56. Turkey Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 57. Argentina Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 58. UAE Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 59. Egypt Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 60. Chile Platinum-based Anticancer Drugs Sales and Growth Rate (2021-2032) & (Tons) Figure 61. Global Platinum-based Anticancer Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Platinum-based Anticancer Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Platinum-based Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 64. North America Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Platinum-based Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Europe Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Platinum-based Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Platinum-based Anticancer Drugs Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Platinum-based Anticancer Drugs Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Platinum-based Anticancer Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Oxaliplatin
  • Carboplatin
  • Nedaplatin
  • Cisplatin
  • Others
Applications
  • Esophageal Cancer
  • Breast Cancer
  • Osteosarcoma
  • Testicular Cancer
  • NSCLC
  • Other
Companies covered
  • Teva
  • Sun Pharmaceutical
  • Qilu Pharmaceutical
  • Nanjing Pharmaceutical Factory
  • Mylan
  • Luoxin
  • Jiangsu Aosaikang Pharmaceutical
  • Jiangsu Hengrui Medicine
  • Fresenius Kabi
  • Yakult honsha
  • Taj Pharmaceuticals
  • Sanofi-Aventis
  • Lingnan Pharmacy
  • Hospira(Pfizer)
  • Hisun Pharmaceutical
  • Hansoh Pharma
  • Dr Reddy's laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Platinum-based Anticancer Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Platinum-based Anticancer Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Platinum-based Anticancer Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Platinum-based Anticancer Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Platinum-based Anticancer Drugs Market Dynamics
  1. 2.1 Platinum-based Anticancer Drugs Industry Trends
  2. 2.2 Platinum-based Anticancer Drugs Industry Drivers
  3. 2.3 Platinum-based Anticancer Drugs Industry Opportunities and Challenges
  4. 2.4 Platinum-based Anticancer Drugs Industry Restraints
3 Platinum-based Anticancer Drugs Market by Manufacturers
  1. 3.1 Global Platinum-based Anticancer Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Platinum-based Anticancer Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Platinum-based Anticancer Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Platinum-based Anticancer Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Platinum-based Anticancer Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Platinum-based Anticancer Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Platinum-based Anticancer Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Platinum-based Anticancer Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Platinum-based Anticancer Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Platinum-based Anticancer Drugs Tier 1, Tier 2, and Tier 3
4 Platinum-based Anticancer Drugs Market by Type
  1. 4.1 Platinum-based Anticancer Drugs Type Introduction
  2. 4.1.1 Oxaliplatin
  3. 4.1.2 Carboplatin
  4. 4.1.3 Nedaplatin
  5. 4.1.4 Cisplatin
  6. 4.1.5 Others
  7. 4.2 Global Platinum-based Anticancer Drugs Sales by Type
  8. 4.2.1 Global Platinum-based Anticancer Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Platinum-based Anticancer Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Platinum-based Anticancer Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Platinum-based Anticancer Drugs Revenue by Type
  12. 4.3.1 Global Platinum-based Anticancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Platinum-based Anticancer Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Platinum-based Anticancer Drugs Revenue Market Share by Type (2021-2032)
5 Platinum-based Anticancer Drugs Market by Application
  1. 5.1 Platinum-based Anticancer Drugs Application Introduction
  2. 5.1.1 Esophageal Cancer
  3. 5.1.2 Breast Cancer
  4. 5.1.3 Osteosarcoma
  5. 5.1.4 Testicular Cancer
  6. 5.1.5 NSCLC
  7. 5.1.6 Other
  8. 5.2 Global Platinum-based Anticancer Drugs Sales by Application
  9. 5.2.1 Global Platinum-based Anticancer Drugs Sales by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Platinum-based Anticancer Drugs Sales by Application (2021-2032)
  11. 5.2.3 Global Platinum-based Anticancer Drugs Sales Market Share by Application (2021-2032)
  12. 5.3 Global Platinum-based Anticancer Drugs Revenue by Application
  13. 5.3.1 Global Platinum-based Anticancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Platinum-based Anticancer Drugs Revenue by Application (2021-2032)
  15. 5.3.3 Global Platinum-based Anticancer Drugs Revenue Market Share by Application (2021-2032)
6 Global Platinum-based Anticancer Drugs Sales by Region
  1. 6.1 Global Platinum-based Anticancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Platinum-based Anticancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Platinum-based Anticancer Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Platinum-based Anticancer Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Platinum-based Anticancer Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Platinum-based Anticancer Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Platinum-based Anticancer Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Platinum-based Anticancer Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Platinum-based Anticancer Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Platinum-based Anticancer Drugs Revenue by Region
  1. 7.1 Global Platinum-based Anticancer Drugs Revenue by Region
  2. 7.1.1 Global Platinum-based Anticancer Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Platinum-based Anticancer Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Platinum-based Anticancer Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Platinum-based Anticancer Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Platinum-based Anticancer Drugs Revenue (2021-2032)
  8. 7.2.2 North America Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Platinum-based Anticancer Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Platinum-based Anticancer Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Platinum-based Anticancer Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Platinum-based Anticancer Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva
  2. 8.1.1 Teva Company Information
  3. 8.1.2 Teva Business Overview
  4. 8.1.3 Teva Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Platinum-based Anticancer Drugs Product Portfolio
  6. 8.1.5 Teva Recent Developments
  7. 8.2 Sun Pharmaceutical
  8. 8.2.1 Sun Pharmaceutical Company Information
  9. 8.2.2 Sun Pharmaceutical Business Overview
  10. 8.2.3 Sun Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  12. 8.2.5 Sun Pharmaceutical Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Nanjing Pharmaceutical Factory
  20. 8.4.1 Nanjing Pharmaceutical Factory Company Information
  21. 8.4.2 Nanjing Pharmaceutical Factory Business Overview
  22. 8.4.3 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Nanjing Pharmaceutical Factory Platinum-based Anticancer Drugs Product Portfolio
  24. 8.4.5 Nanjing Pharmaceutical Factory Recent Developments
  25. 8.5 Mylan
  26. 8.5.1 Mylan Company Information
  27. 8.5.2 Mylan Business Overview
  28. 8.5.3 Mylan Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mylan Platinum-based Anticancer Drugs Product Portfolio
  30. 8.5.5 Mylan Recent Developments
  31. 8.6 Luoxin
  32. 8.6.1 Luoxin Company Information
  33. 8.6.2 Luoxin Business Overview
  34. 8.6.3 Luoxin Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Luoxin Platinum-based Anticancer Drugs Product Portfolio
  36. 8.6.5 Luoxin Recent Developments
  37. 8.7 Jiangsu Aosaikang Pharmaceutical
  38. 8.7.1 Jiangsu Aosaikang Pharmaceutical Company Information
  39. 8.7.2 Jiangsu Aosaikang Pharmaceutical Business Overview
  40. 8.7.3 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Aosaikang Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  42. 8.7.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
  43. 8.8 Jiangsu Hengrui Medicine
  44. 8.8.1 Jiangsu Hengrui Medicine Company Information
  45. 8.8.2 Jiangsu Hengrui Medicine Business Overview
  46. 8.8.3 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Hengrui Medicine Platinum-based Anticancer Drugs Product Portfolio
  48. 8.8.5 Jiangsu Hengrui Medicine Recent Developments
  49. 8.9 Fresenius Kabi
  50. 8.9.1 Fresenius Kabi Company Information
  51. 8.9.2 Fresenius Kabi Business Overview
  52. 8.9.3 Fresenius Kabi Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fresenius Kabi Platinum-based Anticancer Drugs Product Portfolio
  54. 8.9.5 Fresenius Kabi Recent Developments
  55. 8.10 Yakult honsha
  56. 8.10.1 Yakult honsha Company Information
  57. 8.10.2 Yakult honsha Business Overview
  58. 8.10.3 Yakult honsha Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Yakult honsha Platinum-based Anticancer Drugs Product Portfolio
  60. 8.10.5 Yakult honsha Recent Developments
  61. 8.11 Taj Pharmaceuticals
  62. 8.11.1 Taj Pharmaceuticals Company Information
  63. 8.11.2 Taj Pharmaceuticals Business Overview
  64. 8.11.3 Taj Pharmaceuticals Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Taj Pharmaceuticals Platinum-based Anticancer Drugs Product Portfolio
  66. 8.11.5 Taj Pharmaceuticals Recent Developments
  67. 8.12 Sanofi-Aventis
  68. 8.12.1 Sanofi-Aventis Company Information
  69. 8.12.2 Sanofi-Aventis Business Overview
  70. 8.12.3 Sanofi-Aventis Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi-Aventis Platinum-based Anticancer Drugs Product Portfolio
  72. 8.12.5 Sanofi-Aventis Recent Developments
  73. 8.13 Lingnan Pharmacy
  74. 8.13.1 Lingnan Pharmacy Company Information
  75. 8.13.2 Lingnan Pharmacy Business Overview
  76. 8.13.3 Lingnan Pharmacy Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Lingnan Pharmacy Platinum-based Anticancer Drugs Product Portfolio
  78. 8.13.5 Lingnan Pharmacy Recent Developments
  79. 8.14 Hospira(Pfizer)
  80. 8.14.1 Hospira(Pfizer) Company Information
  81. 8.14.2 Hospira(Pfizer) Business Overview
  82. 8.14.3 Hospira(Pfizer) Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hospira(Pfizer) Platinum-based Anticancer Drugs Product Portfolio
  84. 8.14.5 Hospira(Pfizer) Recent Developments
  85. 8.15 Hisun Pharmaceutical
  86. 8.15.1 Hisun Pharmaceutical Company Information
  87. 8.15.2 Hisun Pharmaceutical Business Overview
  88. 8.15.3 Hisun Pharmaceutical Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Hisun Pharmaceutical Platinum-based Anticancer Drugs Product Portfolio
  90. 8.15.5 Hisun Pharmaceutical Recent Developments
  91. 8.16 Hansoh Pharma
  92. 8.16.1 Hansoh Pharma Company Information
  93. 8.16.2 Hansoh Pharma Business Overview
  94. 8.16.3 Hansoh Pharma Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Hansoh Pharma Platinum-based Anticancer Drugs Product Portfolio
  96. 8.16.5 Hansoh Pharma Recent Developments
  97. 8.17 Dr Reddy's laboratories
  98. 8.17.1 Dr Reddy's laboratories Company Information
  99. 8.17.2 Dr Reddy's laboratories Business Overview
  100. 8.17.3 Dr Reddy's laboratories Platinum-based Anticancer Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Dr Reddy's laboratories Platinum-based Anticancer Drugs Product Portfolio
  102. 8.17.5 Dr Reddy's laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Platinum-based Anticancer Drugs Value Chain Analysis
  2. 9.1.1 Platinum-based Anticancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Platinum-based Anticancer Drugs Production Mode & Process
  6. 9.2 Platinum-based Anticancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Platinum-based Anticancer Drugs Distributors
  9. 9.2.3 Platinum-based Anticancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst